Last reviewed · How we verify
TACE+Camrelizumab+Apatinib mesylate
TACE+Camrelizumab+Apatinib mesylate is a Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Hepatocellular carcinoma (HCC), unresectable or advanced stage.
This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis.
This combination therapy uses transarterial chemoembolization (TACE) to deliver chemotherapy directly to liver tumors, combined with camrelizumab (a PD-1 inhibitor) to enhance immune response and apatinib mesylate (a tyrosine kinase inhibitor) to block angiogenesis. Used for Hepatocellular carcinoma (HCC), unresectable or advanced stage.
At a glance
| Generic name | TACE+Camrelizumab+Apatinib mesylate |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor |
| Target | PD-1 (camrelizumab); VEGFR, c-Kit, RET, FLT3 (apatinib mesylate); TACE is procedural |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TACE is a locoregional procedure that embolizes hepatic arteries supplying tumors while delivering chemotherapy directly to the lesion. Camrelizumab blocks PD-1 on T cells, releasing immune checkpoint inhibition to enhance anti-tumor immunity. Apatinib mesylate inhibits VEGFR and other receptor tyrosine kinases to suppress tumor angiogenesis and growth. The combination aims to synergistically improve outcomes in hepatocellular carcinoma by combining locoregional therapy, immunotherapy, and anti-angiogenic therapy.
Approved indications
- Hepatocellular carcinoma (HCC), unresectable or advanced stage
Common side effects
- Hepatic dysfunction / elevated transaminases
- Immune-related adverse events (irAEs)
- Hypertension
- Fatigue
- Diarrhea
- Hand-foot skin reaction
Key clinical trials
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma (PHASE2)
- A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC (PHASE2)
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma (PHASE2, PHASE3)
- A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (PHASE3)
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC (PHASE2)
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma (PHASE2)
- Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TACE+Camrelizumab+Apatinib mesylate CI brief — competitive landscape report
- TACE+Camrelizumab+Apatinib mesylate updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about TACE+Camrelizumab+Apatinib mesylate
What is TACE+Camrelizumab+Apatinib mesylate?
How does TACE+Camrelizumab+Apatinib mesylate work?
What is TACE+Camrelizumab+Apatinib mesylate used for?
Who makes TACE+Camrelizumab+Apatinib mesylate?
What drug class is TACE+Camrelizumab+Apatinib mesylate in?
What development phase is TACE+Camrelizumab+Apatinib mesylate in?
What are the side effects of TACE+Camrelizumab+Apatinib mesylate?
What does TACE+Camrelizumab+Apatinib mesylate target?
Related
- Drug class: All Combination therapy: locoregional chemotherapy + PD-1 inhibitor + tyrosine kinase inhibitor drugs
- Target: All drugs targeting PD-1 (camrelizumab); VEGFR, c-Kit, RET, FLT3 (apatinib mesylate); TACE is procedural
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hepatocellular carcinoma (HCC), unresectable or advanced stage
- Compare: TACE+Camrelizumab+Apatinib mesylate vs similar drugs
- Pricing: TACE+Camrelizumab+Apatinib mesylate cost, discount & access